
### [MONDO:0002363](http://purl.obolibrary.org/obo/MONDO_0002363)
**Label:** papilloma

**Subclasses:** [MONDO:0000935](http://purl.obolibrary.org/obo/MONDO_0000935) (larynx squamous papilloma), [MONDO:0003929](http://purl.obolibrary.org/obo/MONDO_0003929) (micropapillomatosis labialis), [MONDO:0003925](http://purl.obolibrary.org/obo/MONDO_0003925) (ethmoid sinus inverted papilloma), [MONDO:0003923](http://purl.obolibrary.org/obo/MONDO_0003923) (ethmoid sinus Schneiderian papilloma), [MONDO:0001825](http://purl.obolibrary.org/obo/MONDO_0001825) (squamous papilloma), [MONDO:0009837](http://purl.obolibrary.org/obo/MONDO_0009837) (choroid plexus papilloma), [MONDO:0004457](http://purl.obolibrary.org/obo/MONDO_0004457) (maxillary sinus Schneiderian papilloma), [MONDO:0006278](http://purl.obolibrary.org/obo/MONDO_0006278) (lung papilloma), [MONDO:0021276](http://purl.obolibrary.org/obo/MONDO_0021276) (papilloma of buccal mucosa), [MONDO:0021078](http://purl.obolibrary.org/obo/MONDO_0021078) (glandular papilloma), [MONDO:0021275](http://purl.obolibrary.org/obo/MONDO_0021275) (papilloma of eyelid), [MONDO:0006353](http://purl.obolibrary.org/obo/MONDO_0006353) (paranasal sinus Schneiderian papilloma), [MONDO:0004253](http://purl.obolibrary.org/obo/MONDO_0004253) (intraductal breast papillomatosis), [MONDO:0004250](http://purl.obolibrary.org/obo/MONDO_0004250) (extrahepatic bile duct papillary adenoma), [MONDO:0002194](http://purl.obolibrary.org/obo/MONDO_0002194) (vestibular papilloma), [MONDO:0021109](http://purl.obolibrary.org/obo/MONDO_0021109) (inverted urothelial papilloma), [MONDO:0004827](http://purl.obolibrary.org/obo/MONDO_0004827) (esophagus squamous cell papilloma), [MONDO:0001635](http://purl.obolibrary.org/obo/MONDO_0001635) (bladder squamous papilloma), [MONDO:0004509](http://purl.obolibrary.org/obo/MONDO_0004509) (intrahepatic biliary papillomatosis), [MONDO:0004506](http://purl.obolibrary.org/obo/MONDO_0004506) (microscopic breast papilloma), [MONDO:0004507](http://purl.obolibrary.org/obo/MONDO_0004507) (atypical breast papilloma), [MONDO:0004505](http://purl.obolibrary.org/obo/MONDO_0004505) (central breast papilloma), [MONDO:0003611](http://purl.obolibrary.org/obo/MONDO_0003611) (uterine ligament papillary cystadenoma associated with von hippel-lindau disease), [MONDO:0004788](http://purl.obolibrary.org/obo/MONDO_0004788) (cervix squamous papilloma), [MONDO:0003776](http://purl.obolibrary.org/obo/MONDO_0003776) (renal pelvis inverted papilloma), [MONDO:0003777](http://purl.obolibrary.org/obo/MONDO_0003777) (renal pelvis urothelial papilloma), [MONDO:0003455](http://purl.obolibrary.org/obo/MONDO_0003455) (bile duct papillary neoplasm), [MONDO:0004787](http://purl.obolibrary.org/obo/MONDO_0004787) (cervical mullerian papilloma), [MONDO:0004421](http://purl.obolibrary.org/obo/MONDO_0004421) (sclerosing breast papilloma), [MONDO:0004384](http://purl.obolibrary.org/obo/MONDO_0004384) (maxillary sinus inverted papilloma), [MONDO:0002362](http://purl.obolibrary.org/obo/MONDO_0002362) (serous surface papilloma), [MONDO:0003829](http://purl.obolibrary.org/obo/MONDO_0003829) (chromophil adenoma of the kidney), [MONDO:0002537](http://purl.obolibrary.org/obo/MONDO_0002537) (inverted papilloma), [MONDO:0002534](http://purl.obolibrary.org/obo/MONDO_0002534) (fallopian tube papilloma), [MONDO:0005605](http://purl.obolibrary.org/obo/MONDO_0005605) (transitional cell papilloma), [MONDO:0002533](http://purl.obolibrary.org/obo/MONDO_0002533) (papillary adenoma), [MONDO:0002536](http://purl.obolibrary.org/obo/MONDO_0002536) (skin papilloma), [MONDO:0002535](http://purl.obolibrary.org/obo/MONDO_0002535) (verrucous papilloma), [MONDO:0004353](http://purl.obolibrary.org/obo/MONDO_0004353) (extrahepatic biliary papillomatosis), [MONDO:0003064](http://purl.obolibrary.org/obo/MONDO_0003064) (inverted transitional papilloma), [MONDO:0021097](http://purl.obolibrary.org/obo/MONDO_0021097) (intraductal breast papilloma), [MONDO:0001680](http://purl.obolibrary.org/obo/MONDO_0001680) (vaginal mullerian papilloma), [MONDO:0021091](http://purl.obolibrary.org/obo/MONDO_0021091) (papillary cystadenoma), [MONDO:0001779](http://purl.obolibrary.org/obo/MONDO_0001779) (vaginal squamous papilloma), [MONDO:0003955](http://purl.obolibrary.org/obo/MONDO_0003955) (juvenile breast papillomatosis), [MONDO:0003831](http://purl.obolibrary.org/obo/MONDO_0003831) (type 2 papillary adenoma of the kidney), [MONDO:0004326](http://purl.obolibrary.org/obo/MONDO_0004326) (sphenoid sinus inverted papilloma), [MONDO:0004327](http://purl.obolibrary.org/obo/MONDO_0004327) (sphenoid sinus Schneiderian papilloma), [MONDO:0004448](http://purl.obolibrary.org/obo/MONDO_0004448) (frontal sinus inverted papilloma), [MONDO:0003752](http://purl.obolibrary.org/obo/MONDO_0003752) (frontal sinus Schneiderian papilloma), [MONDO:0003873](http://purl.obolibrary.org/obo/MONDO_0003873) (ovarian surface papilloma), [MONDO:0002221](http://purl.obolibrary.org/obo/MONDO_0002221) (urethral urothelial papilloma), [MONDO:0003830](http://purl.obolibrary.org/obo/MONDO_0003830) (type 1 papillary adenoma of the kidney), [MONDO:0003753](http://purl.obolibrary.org/obo/MONDO_0003753) (nasal vestibule squamous papilloma), [MONDO:0004204](http://purl.obolibrary.org/obo/MONDO_0004204) (squamous cell papilloma of skin), [MONDO:0006149](http://purl.obolibrary.org/obo/MONDO_0006149) (clear cell papillary cystadenoma), [MONDO:0003872](http://purl.obolibrary.org/obo/MONDO_0003872) (ovarian papillary cystadenoma), [MONDO:0002388](http://purl.obolibrary.org/obo/MONDO_0002388) (intracystic papillary adenoma), [MONDO:0002063](http://purl.obolibrary.org/obo/MONDO_0002063) (breast papillomatosis), [MONDO:0004043](http://purl.obolibrary.org/obo/MONDO_0004043) (ureter inverted papilloma), [MONDO:0004044](http://purl.obolibrary.org/obo/MONDO_0004044) (ureter urothelial papilloma), [MONDO:0002060](http://purl.obolibrary.org/obo/MONDO_0002060) (intraductal papilloma), [MONDO:0004041](http://purl.obolibrary.org/obo/MONDO_0004041) (urothelial papilloma), [MONDO:0004042](http://purl.obolibrary.org/obo/MONDO_0004042) (urethra inverted papilloma), [MONDO:0004040](http://purl.obolibrary.org/obo/MONDO_0004040) (urinary bladder inverted papilloma), 

**Mapped go classes:** [GO:0007050](http://purl.obolibrary.org/obo/GO_0007050) (cell cycle arrest), [GO:0016525](http://purl.obolibrary.org/obo/GO_0016525) (negative regulation of angiogenesis), [GO:0016604](http://purl.obolibrary.org/obo/GO_0016604) (nuclear body), [GO:0003690](http://purl.obolibrary.org/obo/GO_0003690) (double-stranded DNA binding), [GO:0042771](http://purl.obolibrary.org/obo/GO_0042771) (intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator), [GO:0005667](http://purl.obolibrary.org/obo/GO_0005667) (transcription factor complex), [GO:0002039](http://purl.obolibrary.org/obo/GO_0002039) (p53 binding), [GO:0051289](http://purl.obolibrary.org/obo/GO_0051289) (protein homotetramerization), [GO:0005669](http://purl.obolibrary.org/obo/GO_0005669) (transcription factor TFIID complex), [GO:0045893](http://purl.obolibrary.org/obo/GO_0045893) (positive regulation of transcription, DNA-templated), [GO:0060729](http://purl.obolibrary.org/obo/GO_0060729) (intestinal epithelial structure maintenance), [GO:0006914](http://purl.obolibrary.org/obo/GO_0006914) (autophagy), [GO:0006915](http://purl.obolibrary.org/obo/GO_0006915) (apoptotic process), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0071456](http://purl.obolibrary.org/obo/GO_0071456) (cellular response to hypoxia), [GO:0010332](http://purl.obolibrary.org/obo/GO_0010332) (response to gamma radiation), [GO:0061484](http://purl.obolibrary.org/obo/GO_0061484) (hematopoietic stem cell homeostasis), [GO:0000785](http://purl.obolibrary.org/obo/GO_0000785) (chromatin), [GO:0043280](http://purl.obolibrary.org/obo/GO_0043280) (positive regulation of cysteine-type endopeptidase activity involved in apoptotic process), [GO:0000077](http://purl.obolibrary.org/obo/GO_0000077) (DNA damage checkpoint), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0005515](http://purl.obolibrary.org/obo/GO_0005515) (protein binding), [GO:0048730](http://purl.obolibrary.org/obo/GO_0048730) (epidermis morphogenesis), [GO:0046872](http://purl.obolibrary.org/obo/GO_0046872) (metal ion binding), [GO:0010165](http://purl.obolibrary.org/obo/GO_0010165) (response to X-ray), [GO:0031065](http://purl.obolibrary.org/obo/GO_0031065) (positive regulation of histone deacetylation), [GO:0090398](http://purl.obolibrary.org/obo/GO_0090398) (cellular senescence), [GO:0044212](http://purl.obolibrary.org/obo/GO_0044212) (transcription regulatory region DNA binding), [GO:0045786](http://purl.obolibrary.org/obo/GO_0045786) (negative regulation of cell cycle), [GO:0045787](http://purl.obolibrary.org/obo/GO_0045787) (positive regulation of cell cycle), [GO:0043565](http://purl.obolibrary.org/obo/GO_0043565) (sequence-specific DNA binding), [GO:0097193](http://purl.obolibrary.org/obo/GO_0097193) (intrinsic apoptotic signaling pathway), [GO:0009411](http://purl.obolibrary.org/obo/GO_0009411) (response to UV), [GO:0045944](http://purl.obolibrary.org/obo/GO_0045944) (positive regulation of transcription by RNA polymerase II), [GO:0043525](http://purl.obolibrary.org/obo/GO_0043525) (positive regulation of neuron apoptotic process), [GO:0043249](http://purl.obolibrary.org/obo/GO_0043249) (erythrocyte maturation), [GO:0006978](http://purl.obolibrary.org/obo/GO_0006978) (DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator), [GO:0000122](http://purl.obolibrary.org/obo/GO_0000122) (negative regulation of transcription by RNA polymerase II), [GO:0003700](http://purl.obolibrary.org/obo/GO_0003700) (DNA binding transcription factor activity), [GO:0051782](http://purl.obolibrary.org/obo/GO_0051782) (negative regulation of cell division), [GO:2000779](http://purl.obolibrary.org/obo/GO_2000779) (regulation of double-strand break repair), [GO:0051262](http://purl.obolibrary.org/obo/GO_0051262) (protein tetramerization), [GO:0034644](http://purl.obolibrary.org/obo/GO_0034644) (cellular response to UV), [GO:1902262](http://purl.obolibrary.org/obo/GO_1902262) (apoptotic process involved in blood vessel morphogenesis), [GO:0006351](http://purl.obolibrary.org/obo/GO_0006351) (transcription, DNA-templated), [GO:0031571](http://purl.obolibrary.org/obo/GO_0031571) (mitotic G1 DNA damage checkpoint), [GO:0007283](http://purl.obolibrary.org/obo/GO_0007283) (spermatogenesis), [GO:0006355](http://purl.obolibrary.org/obo/GO_0006355) (regulation of transcription, DNA-templated), [GO:0048821](http://purl.obolibrary.org/obo/GO_0048821) (erythrocyte development), [GO:0003682](http://purl.obolibrary.org/obo/GO_0003682) (chromatin binding), [GO:0003684](http://purl.obolibrary.org/obo/GO_0003684) (damaged DNA binding), [GO:0007049](http://purl.obolibrary.org/obo/GO_0007049) (cell cycle), [GO:0060216](http://purl.obolibrary.org/obo/GO_0060216) (definitive hemopoiesis), [GO:0005657](http://purl.obolibrary.org/obo/GO_0005657) (replication fork), [GO:0003677](http://purl.obolibrary.org/obo/GO_0003677) (DNA binding), [GO:0051597](http://purl.obolibrary.org/obo/GO_0051597) (response to methylmercury), [GO:0031647](http://purl.obolibrary.org/obo/GO_0031647) (regulation of protein stability), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0010526](http://purl.obolibrary.org/obo/GO_0010526) (negative regulation of transposition, RNA-mediated), [GO:0005739](http://purl.obolibrary.org/obo/GO_0005739) (mitochondrion), [GO:0043065](http://purl.obolibrary.org/obo/GO_0043065) (positive regulation of apoptotic process), 

**Class expressions from DL-Learner:**

- [GO:0071456](http://purl.obolibrary.org/obo/GO_0071456) (cellular response to hypoxia) 54.17%
- [GO:0044783](http://purl.obolibrary.org/obo/GO_0044783) (G1 DNA damage checkpoint) 54.17%
- [GO:0042772](http://purl.obolibrary.org/obo/GO_0042772) (DNA damage response, signal transduction resulting in transcription) 54.17%
- [GO:0042771](http://purl.obolibrary.org/obo/GO_0042771) (intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator) 54.17%
- [GO:0031571](http://purl.obolibrary.org/obo/GO_0031571) (mitotic G1 DNA damage checkpoint) 54.17%
- [GO:0008630](http://purl.obolibrary.org/obo/GO_0008630) (intrinsic apoptotic signaling pathway in response to DNA damage) 54.17%
- [GO:0006978](http://purl.obolibrary.org/obo/GO_0006978) (DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator) 54.17%
- [GO:0001666](http://purl.obolibrary.org/obo/GO_0001666) (response to hypoxia) 54.17%
- [GO:0044773](http://purl.obolibrary.org/obo/GO_0044773) (mitotic DNA damage checkpoint) and [GO:2000134](http://purl.obolibrary.org/obo/GO_2000134) (negative regulation of G1/S transition of mitotic cell cycle) 54.17%
- [GO:0044773](http://purl.obolibrary.org/obo/GO_0044773) (mitotic DNA damage checkpoint) and [GO:2000045](http://purl.obolibrary.org/obo/GO_2000045) (regulation of G1/S transition of mitotic cell cycle) 54.17%
- [GO:0044773](http://purl.obolibrary.org/obo/GO_0044773) (mitotic DNA damage checkpoint) and [GO:1902807](http://purl.obolibrary.org/obo/GO_1902807) (negative regulation of cell cycle G1/S phase transition) 54.17%
- [GO:0044773](http://purl.obolibrary.org/obo/GO_0044773) (mitotic DNA damage checkpoint) and [GO:1902806](http://purl.obolibrary.org/obo/GO_1902806) (regulation of cell cycle G1/S phase transition) 54.17%
- [GO:0044773](http://purl.obolibrary.org/obo/GO_0044773) (mitotic DNA damage checkpoint) and [GO:0044819](http://purl.obolibrary.org/obo/GO_0044819) (mitotic G1/S transition checkpoint) 54.17%
- [GO:0044773](http://purl.obolibrary.org/obo/GO_0044773) (mitotic DNA damage checkpoint) and [GO:0044783](http://purl.obolibrary.org/obo/GO_0044783) (G1 DNA damage checkpoint) 54.17%
- [GO:0042772](http://purl.obolibrary.org/obo/GO_0042772) (DNA damage response, signal transduction resulting in transcription) and [GO:0072331](http://purl.obolibrary.org/obo/GO_0072331) (signal transduction by p53 class mediator) 54.17%


